Rothschild & Co Redburn initiated coverage of MoonLake Immunotherapeutics (MLTX) with a Neutral rating and $65 price target Published first on ...

When building your watch list, look for stocks with an 80 or higher RS Rating. MoonLake Immunotherap MLTX is one stock that ...

MoonLake has recently announced the successful outcome of its end-of-Phase 2 interactions with the U.S. Food and Drug Administration (FDA) the E.U. European Medicines Agency (EMA), with both ...

MoonLake will be hosting an R&D Day for investors and analysts in San Diego, USA on Sunday, March 10 alongside the American Academy of Dermatology (AAD) annual meeting.

MoonLake Immunotherapeutics (NASDAQ:MLTX) is a good speculative biotech play to look into. That's because it reported positive results from a phase 2 study using its drug sonelokimab for the ...

MoonLake stock has seen a 400% increase in value since its listing on the Nasdaq, and has raised over $450 million through equity offerings. Read more here.

MoonLake also announced a Capital Markets Day to be held in New York at NASDAQ, including a virtual webcast format, on September 11 th 2023. This session will be used to discuss the PsA market and ...

What happenedShares of the clinical-stage biotech MoonLake Immunotherapeutics (NASDAQ: MLTX) jumped by an eye-popping 78.8% over the first three and a half days of trading this week, according to ...

For two days starting on Sunday, Moonlake Immunotherapeutics happily crunched numbers and shared results from a mid-stage clinical trial that depicted its experimental antibody in the most ...

MoonLake Immunotherapeutics (“MoonLake”; Nasdaq: MLTX), a clinical-stage biotechnology company focused on creating next-level therapies for inflammato ...

MoonLake Immunotherapeutics (NASDAQ: MLTX) has reportedly engaged an investment bank as the Swiss company looks for a potential sale. The company focuses on developing antibody-derived treatments ...